Trial Profile
A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms PrefHer
- Sponsors Roche
- 28 Feb 2019 According to the Genentech media release, based on the data from this study, the U.S. Food and Drug Administration has approved a subcutaneous injection of Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-positive early breast cancer in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.
- 27 Sep 2017 Results of final analysis (3 years' follow-up) published in the European Journal of Cancer
- 11 Oct 2016 Results assessing efficacy presented at the 41st European Society for Medical Oncology Congress (2016).